Kenneth W. Liechty
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Kenneth W. Liechty has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
Liping Zhang
The Children’s Hospital of Philadelphia, Philadelphia, PA
5 shared publicationsAntoneta Radu
The Children’s Hospital of Philadelphia, Philadelphia, PA
4 shared publicationsAndrea T. Badillo
Department of Surgery, The Center for Fetal Research, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA
3 shared publicationsEnrico Danzer
The University of Pennsylvania School of Medicine, Philadelphia, PA
2 shared publicationsMarcus G. Davey
The Children’s Hospital of Philadelphia, Philadelphia, PA
2 shared publicationsAlan W. Flake
1 shared publication
Latest Publications
- 14 September 2010
- Published by Wiley in Wound Repair and Regeneration
- Vol. 18 (5) , 543-549
Fetal tendon wound size modulates wound gene expression and subsequent wound phenotype
The fetal response to small tendon injury results in regenerative or scarless healing and is characterized by a markedly diminished cellular inflammatory response, lack of fibroplasia, and restoration of normal tissue architecture. We hypothesized that an increasing fetal tendon wound size would lead to increased wound inflammation and a change from regenerative to reparative healing and scar formation. We created small or large tendon wounds in early gestation fetal sheep and used histology to assess tissue architecture, immunohistochemistry to assess the cellular inflammatory response, ovine‐specific gene microarrays, and real‐time reverse transcription‐polymerase chain reaction to measure the gene expression in response to injury. Small tendon wounds showed a regenerative healing phenotype with orderly deposition of collagen fibers while large tendon wounds showed disorderly collagen deposition consistent with scar formation. Small tendon wounds had few inflammatory cells at 7 and 28 days after injury, whereas the large wounds showed a significant inflammatory cell infiltrate at 7 days that resolved by 28 days. At 3 days, the differential expression of genes involved in the response to injury and inflammation were seen between large and small tendon wounds. By real‐time polymerase chain reaction at 7 days, large tendon wounds also had significantly increased expression of interleukin‐6, interleukin‐8, transforming growth factor‐β1, and transforming growth factor‐β3, compared with the small wounds. Increasing the fetal tendon wound size results in increased proinflammatory gene expression, inflammatory cell infiltration, and a change from regenerative to reparative healing. This model allows the process of regenerative healing to be examined without the confounding variable of gestational age.
- 14 September 2010
- Published by Wiley in Wound Repair and Regeneration
- Vol. 18 (5) , 543-549
Fetal tendon wound size modulates wound gene expression and subsequent wound phenotype
The fetal response to small tendon injury results in regenerative or scarless healing and is characterized by a markedly diminished cellular inflammatory response, lack of fibroplasia, and restoration of normal tissue architecture. We hypothesized that an increasing fetal tendon wound size would lead to increased wound inflammation and a change from regenerative to reparative healing and scar formation. We created small or large tendon wounds in early gestation fetal sheep and used histology to assess tissue architecture, immunohistochemistry to assess the cellular inflammatory response, ovine‐specific gene microarrays, and real‐time reverse transcription‐polymerase chain reaction to measure the gene expression in response to injury. Small tendon wounds showed a regenerative healing phenotype with orderly deposition of collagen fibers while large tendon wounds showed disorderly collagen deposition consistent with scar formation. Small tendon wounds had few inflammatory cells at 7 and 28 days after injury, whereas the large wounds showed a significant inflammatory cell infiltrate at 7 days that resolved by 28 days. At 3 days, the differential expression of genes involved in the response to injury and inflammation were seen between large and small tendon wounds. By real‐time polymerase chain reaction at 7 days, large tendon wounds also had significantly increased expression of interleukin‐6, interleukin‐8, transforming growth factor‐β1, and transforming growth factor‐β3, compared with the small wounds. Increasing the fetal tendon wound size results in increased proinflammatory gene expression, inflammatory cell infiltration, and a change from regenerative to reparative healing. This model allows the process of regenerative healing to be examined without the confounding variable of gestational age.
- 30 September 2008
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 207 (3) , S59-S60
Increasing fetal dermal wound size results in increased proinflammatory cytokine production, increased inflammation, and fetal dermal scar formation
- 30 September 2008
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 207 (3) , S59-S60
Increasing fetal dermal wound size results in increased proinflammatory cytokine production, increased inflammation, and fetal dermal scar formation
- 1 July 2008
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 128 (7) , 1852-1860
IL-10 Overexpression Decreases Inflammatory Mediators and Promotes Regenerative Healing in an Adult Model of Scar Formation
- 1 July 2008
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 128 (7) , 1852-1860
IL-10 Overexpression Decreases Inflammatory Mediators and Promotes Regenerative Healing in an Adult Model of Scar Formation
- 10 March 2008
- Published by Wiley in Prenatal Diagnosis
- Vol. 28 (7) , 612-618
Postnatal management and outcome of prenatally diagnosed lung lesions
Advancements in fetal diagnostic imaging have increased prenatal diagnosis of many fetal anomalies. The purpose of this chapter is to review the etiology and natural history of prenatally diagnosed cystic lung lesions, including congenital cystic adenomatoid malformations (CCAM), pulmonary sequestrations (PSs), hybrid lesions, and bronchogenic cysts, and then discuss current concepts in the management and outcome of these lesions. Copyright © 2008 John Wiley & Sons, Ltd.
- 10 March 2008
- Published by Wiley in Prenatal Diagnosis
- Vol. 28 (7) , 612-618
Postnatal management and outcome of prenatally diagnosed lung lesions
Advancements in fetal diagnostic imaging have increased prenatal diagnosis of many fetal anomalies. The purpose of this chapter is to review the etiology and natural history of prenatally diagnosed cystic lung lesions, including congenital cystic adenomatoid malformations (CCAM), pulmonary sequestrations (PSs), hybrid lesions, and bronchogenic cysts, and then discuss current concepts in the management and outcome of these lesions. Copyright © 2008 John Wiley & Sons, Ltd.
- 6 March 2008
- Published by Wiley in Prenatal Diagnosis
- Vol. 28 (7) , 656-666
Postnatal management of prenatally diagnosed abdominal masses and anomalies
Rapid advancement in fetal diagnostic imaging has increased our ability to diagnose a multitude of anomalies in the prenatal period. The purpose of this chapter is to review our current understanding of prenatally diagnosed intra‐abdominal lesions, and describe the current guidelines for the postnatal management and subsequent outcome for these lesions. Copyright © 2008 John Wiley & Sons, Ltd.
- 6 March 2008
- Published by Wiley in Prenatal Diagnosis
- Vol. 28 (7) , 656-666
Postnatal management of prenatally diagnosed abdominal masses and anomalies
Rapid advancement in fetal diagnostic imaging has increased our ability to diagnose a multitude of anomalies in the prenatal period. The purpose of this chapter is to review our current understanding of prenatally diagnosed intra‐abdominal lesions, and describe the current guidelines for the postnatal management and subsequent outcome for these lesions. Copyright © 2008 John Wiley & Sons, Ltd.
- 1 February 2008
- Published by Elsevier in Seminars in Pediatric Surgery
- Vol. 17 (1) , 9-16
Pulmonary vascular malformations
- 1 February 2008
- Published by Elsevier in Seminars in Pediatric Surgery
- Vol. 17 (1) , 9-16
Pulmonary vascular malformations
- 1 January 2008
- Published by Elsevier in Cytotherapy
- Vol. 10 (6) , 543-550
Multipotent adult progenitor cells: their role in wound healing and the treatment of dermal wounds
The use of cellular therapy in the treatment of dermal wounds is currently an active area of investigation. Multipotent adult progenitor cells (MAPC) are an attractive choice for cytotherapy because they have a large proliferative potential, the ability to differentiate into different cell types and produce a variety of cytokines and growth factors important to wound healing. Whole bone marrow (BM) was one of the initial attempts to treat impaired wounds. While it has shown some promise, the low frequency of progenitor cell populations in BM and the large number of inflammatory cells make it less attractive. Multipotent mesenchymal stromal cells (MSC) and endothelial progenitor cells are populations of BM-derived progenitor cells that have been isolated and used to treat chronic wounds with some success. Skin-derived MAPC are another heterogeneous population of progenitor cells present in the skin with the potential to differentiate into skin elements and participate in wound healing. All of these progenitor cell populations are potential sources for cytotherapy of wounds. This review focused on the contribution of adult progenitor cell populations to dermal wound healing and their potential for use in cytotherapy.
- 1 January 2008
- Published by Elsevier in Cytotherapy
- Vol. 10 (6) , 543-550
Multipotent adult progenitor cells: their role in wound healing and the treatment of dermal wounds
The use of cellular therapy in the treatment of dermal wounds is currently an active area of investigation. Multipotent adult progenitor cells (MAPC) are an attractive choice for cytotherapy because they have a large proliferative potential, the ability to differentiate into different cell types and produce a variety of cytokines and growth factors important to wound healing. Whole bone marrow (BM) was one of the initial attempts to treat impaired wounds. While it has shown some promise, the low frequency of progenitor cell populations in BM and the large number of inflammatory cells make it less attractive. Multipotent mesenchymal stromal cells (MSC) and endothelial progenitor cells are populations of BM-derived progenitor cells that have been isolated and used to treat chronic wounds with some success. Skin-derived MAPC are another heterogeneous population of progenitor cells present in the skin with the potential to differentiate into skin elements and participate in wound healing. All of these progenitor cell populations are potential sources for cytotherapy of wounds. This review focused on the contribution of adult progenitor cell populations to dermal wound healing and their potential for use in cytotherapy.
- 19 September 2007
- Published by Wiley in Wound Repair and Regeneration
- Vol. 15 (5) , 736-747
Stromal progenitor cell therapy corrects the wound‐healing defect in the ischemic rabbit ear model of chronic wound repair
Chronic wounds create a formidable clinical problem resulting in considerable morbidity and healthcare expenditure. The etiology for wound healing impairment appears to be multifactorial; however, ischemia is a common factor in most types of chronic wounds. Ideal therapy for such wounds would be to correct deficiencies in growth factors and matrix components and provide cellular precursors required for timely wound closure. We hypothesized that stromal progenitor cell (SPC) therapy could correct the ischemic wound‐healing defect through both direct and indirect mechanisms. To test this hypothesis, we used the ischemic rabbit ear model of chronic wound healing. We found that treatment of the wounds with SPCs was able to reverse the ischemic wound‐healing impairment, with improved granulation tissue formation and reepithelialization compared with vehicle or bone marrow mononuclear cell controls. In vitro, SPCs were found to produce factors involved in angiogenesis and reepithelialization, and extracellular matrix components, providing evidence for both direct and indirect mechanisms for the observed correction of the healing impairment in these wounds. Treatment of ischemic wounds with SPCs can dramatically improve wound healing and provides a rationale for further studies focused on SPCs as a potential cellular therapy in impaired wound healing.
- 19 September 2007
- Published by Wiley in Wound Repair and Regeneration
- Vol. 15 (5) , 736-747
Stromal progenitor cell therapy corrects the wound‐healing defect in the ischemic rabbit ear model of chronic wound repair
Chronic wounds create a formidable clinical problem resulting in considerable morbidity and healthcare expenditure. The etiology for wound healing impairment appears to be multifactorial; however, ischemia is a common factor in most types of chronic wounds. Ideal therapy for such wounds would be to correct deficiencies in growth factors and matrix components and provide cellular precursors required for timely wound closure. We hypothesized that stromal progenitor cell (SPC) therapy could correct the ischemic wound‐healing defect through both direct and indirect mechanisms. To test this hypothesis, we used the ischemic rabbit ear model of chronic wound healing. We found that treatment of the wounds with SPCs was able to reverse the ischemic wound‐healing impairment, with improved granulation tissue formation and reepithelialization compared with vehicle or bone marrow mononuclear cell controls. In vitro, SPCs were found to produce factors involved in angiogenesis and reepithelialization, and extracellular matrix components, providing evidence for both direct and indirect mechanisms for the observed correction of the healing impairment in these wounds. Treatment of ischemic wounds with SPCs can dramatically improve wound healing and provides a rationale for further studies focused on SPCs as a potential cellular therapy in impaired wound healing.
- 24 April 2007
- Published by Springer Nature in Cell and tissue research
- Vol. 329 (2) , 301-311
Treatment of diabetic wounds with fetal murine mesenchymal stromal cells enhances wound closure
Diabetes impairs multiple aspects of the wound-healing response. Delayed wound healing continues to be a significant healthcare problem for which effective therapies are lacking. We have hypothesized that local delivery of mesenchymal stromal cells (MSC) at a wound might correct many of the wound-healing impairments seen in diabetic lesions. We treated excisional wounds of genetically diabetic (Db-/Db-) mice and heterozygous controls with either MSC, CD45+ cells, or vehicle. At 7 days, treatment with MSC resulted in a decrease in the epithelial gap from 3.2 ± 0.5 mm in vehicle-treated wounds to 1.3 ± 0.4 mm in MSC-treated wounds and an increase in granulation tissue from 0.8 ± 0.3 mm2 to 2.4 ± 0.6 mm2, respectively (mean ± SD, P < 0.04). MSC-treated wounds also displayed a higher density of CD31+ vessels and exhibited increases in the production of mRNA for epidermal growth factor, transforming growth factor beta 1, vascular endothelial growth factor, and stromal-derived growth factor 1-alpha. MSC also demonstrated greater contractile ability than fibroblast controls in a collagen gel contraction assay. The effects of locally applied MSC are thus sufficient to improve healing in diabetic mice. Possible mechanisms of this effect include augmented local growth-factor production, improved neovascularization, enhanced cellular recruitment to wounds, and improved wound contraction.
- 24 April 2007
- Published by Springer Nature in Cell and tissue research
- Vol. 329 (2) , 301-311
Treatment of diabetic wounds with fetal murine mesenchymal stromal cells enhances wound closure
Diabetes impairs multiple aspects of the wound-healing response. Delayed wound healing continues to be a significant healthcare problem for which effective therapies are lacking. We have hypothesized that local delivery of mesenchymal stromal cells (MSC) at a wound might correct many of the wound-healing impairments seen in diabetic lesions. We treated excisional wounds of genetically diabetic (Db-/Db-) mice and heterozygous controls with either MSC, CD45+ cells, or vehicle. At 7 days, treatment with MSC resulted in a decrease in the epithelial gap from 3.2 ± 0.5 mm in vehicle-treated wounds to 1.3 ± 0.4 mm in MSC-treated wounds and an increase in granulation tissue from 0.8 ± 0.3 mm2 to 2.4 ± 0.6 mm2, respectively (mean ± SD, P < 0.04). MSC-treated wounds also displayed a higher density of CD31+ vessels and exhibited increases in the production of mRNA for epidermal growth factor, transforming growth factor beta 1, vascular endothelial growth factor, and stromal-derived growth factor 1-alpha. MSC also demonstrated greater contractile ability than fibroblast controls in a collagen gel contraction assay. The effects of locally applied MSC are thus sufficient to improve healing in diabetic mice. Possible mechanisms of this effect include augmented local growth-factor production, improved neovascularization, enhanced cellular recruitment to wounds, and improved wound contraction.
- 1 August 2006
- Published by Elsevier in Journal of Pediatric Surgery
- Vol. 41 (8) , e1-e5
Wilms' tumor arising within a mediastinal teratoma
- 1 August 2006
- Published by Elsevier in Journal of Pediatric Surgery
- Vol. 41 (8) , e1-e5
Wilms' tumor arising within a mediastinal teratoma